SHENZHEN, China, Aug. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), (http://www.htdsmedical.com) subsidiary, Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) announced today that the general manager of Mellow Hope paid a visit to Chile, in regards to a significant new business development opportunity related to Mellow Hope's MedVac flu vaccine products. The company intends to participate in a formal tender process to supply a couple separate orders to a couple separate and unrelated entities in Chile.
The company is pleased to report that the company has made a significant progress to secure these couple of interests in Chile. Mellow Hope is tendering between 2,000,000 to 5,000,000 doses of Flu vaccine, for the Chilean market.
Mr. Eric Yuan, Spokesperson for the company, said, "The reason this announcement is being made is three fold. Firstly, to keep our followers and shareholders advised of our daily and ongoing business activities. Secondly certain Mellow Hope filings with the Chilean authorities in regards to the tender process will be made public shortly. Although available in Spanish only, the Company felt that shareholders should be advised directly, in order to avoid any distortions or rumors should news of these filings leak out through other channels. Finally, should the bid submission be successful, this may very well be the largest single order the company will fulfill to date, and would represent a material business development of interest to our shareholders."
In order to highlight our excitement and expectations Mellow Hope's usual tender is in the 250,000 doses of Flu vaccine range such as our recent announcement July 15, 2009, Indonesia transaction. http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds and our July 10th 2009 India news release http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds
Again, as this is worth repeating Mellow Hope is tendering between 2,000,000 to 5,000,000 doses of Flu vaccine, for the Chilean market.
Mellow Hope product specifications and details can be viewed by visiting our web page directly http://www.mellowhope.com/en/ProductView.asp?ID=51
This is an important update to our followers. The company will release further updates as they become available, and will refer back to this news release periodically to avoid any confusion, due to the fact that there are multiple pending tenders in Chile.
In other Company news, the company intends to release its Q2 financials on or before August 15th due date, shortly followed by its IP position developments, and some positive strides made in that regard. The documents are currently being translated from Chinese to North American standards. The company is responding to its shareholders requests that the information currently displayed on Pink Sheets be updated. This update will be processed over the weekend. The company expects Pink Sheets to display the update(s) shortly in accordance with their verification policies, shortly thereafter.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
This is not an offer to buy or sell securities in any jurisdiction. This communication is for informational purposes only. This third party publication is not prepared or approved by MMG (Mina Mar Group) and therefore, may not meet research disclosure requirements applicable to MMG. The contents herein may be subject to copyright laws and any dissemination in whole or in part electronically or otherwise may not be shared with others without the author's prior written consent, which consent can unreasonably be withheld. We do not give legal or security trading or accounting advice of any kind. We are not a licensed broker dealer and do not claim to be. We make no representations as to the suitability of any transaction at any time. The opinions, estimates and projections contained in the publication are those of the author as of the date indicated and are subject to change without notice. MMG makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors or omissions which may be contained therein and accepts no liability whatsoever for any loss arising from any use of or reliance on the report or its contents. MMG its affiliates and/or their respective officers, directors, independent contractors or employees may from time to time acquire, hold or sell securities of issuers mentioned in the publication, related securities, or options, futures or other derivative instruments based thereon. MMG may act as financial advisor and/or consultant for certain of the issuers mentioned therein and may receive remuneration for same. MMG or its affiliates may have consulting arrangements with, or provide other remunerated services to, the issuers mentioned herein. The reader should assume that MMG or its affiliates may have a conflict of interest, and should not rely solely on this publication in evaluating whether or not to buy or sell securities of issuers discussed herein.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved